News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cempra Pharmaceuticals, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference


8/30/2012 12:37:30 PM

CHAPEL HILL, N.C., Aug. 29, 2012 /PRNewswire/ -- Cempra, Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the 2012 Stifel Nicolaus Healthcare Conference at 10:20 a.m. EDT, Sept. 5, at the Four Seasons Hotel in Boston, and at the NewsMakers in the Biotech Industry conference at 9:30 a.m. EDT, Sept. 7, at the Millennium Broadway Hotel & Conference Center in New York. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and uncomplicated gonococcal infection and TAKSTA for the oral treatment of prosthetic joint infections from gram positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA).

The presentation at the Stifel Nicolaus Healthcare Conference will be webcast live under the events section of Cempra's website at www.cempra.com and will be archived there following the presentation for 30 days. Please connect to Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com

SOURCE Cempra, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES